The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Exploring estrogen receptor roles and targeted therapy in NSCLC
Robert Hsu, MD, Keck School of Medicine, USC, Los Angeles, CA, discusses role of estrogen receptor (ER) in non-small cell lung cancer (NSCLC), particularly the impact of the expressions of ER-alpha (ESR1), ER-beta (ESR2) on survival rates. High ESR1 correlated with KRAS/EGFR mutations, especially in females, while high ESR2 levels had a balanced gender ratio and fewer mutations. High ESR1 and ESR2 expression were linked to increased MAPK pathway interaction and better median overall survival (OS). Patients receiving osimertinib and sotorasib with high ESR1 and low ESR2 had the longest survival, suggesting potential benefits of targeted therapy for KRAS/EGFR and ESR1/ESR2 mutations in NSCLC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – DAVA Oncology; The Dedham Group
Consulting or Advisory Role – Takeda; Targeted Oncology
